Issue 12 - Research update

Updated 3 weeks ago by Lynn Joels

NAC could improve dopamine levels in Parkinson's disease

This study assessed the biological and clinical effects in patients with Parkinson’s disease (PD) of N-acetyl-cysteine (NAC), the prodrug to L-cysteine, a precursor to the natural biological antioxidant glutathione. The results suggest NAC may positively affect the dopaminergic system in patients with PD, with corresponding positive clinical effects. The study found improvements in dopamine levels, as well as improvements in clinical evaluations of the patients' mental and physical abilities.

Take a look at the full study here:

https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.1548?referrer_access_token=XAKJUOUWPWof1wRwC9bd1k4keas67K9QMdWULTWMo8M0DNXNWNxhf2csGb9a2-zpBDX3rU7fwQlrdyWUXJ1it_SIOqHHC55tz6t6QTX1nB5oBI42mbTfINB_U9IJHIzhuV4FuDPFsP8FuC_ZC5J6KA%3D%3D

Ref:

Monti, D.A. et al. (2019) N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease, Clinical Pharmacology & Therapeuticsdoi.org/10.1002/cpt.1548.


How did we do?